Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

44211 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ABACAVIR AND LAMIVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ENTECAVIR LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ABACAVIR , LAMIVUDINE AND ZIDOVUDINE ABACAVIR SULFATE AND LAMIVUDINE ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE DOLUTEGRAVIR SODIUM AND LAMIVUDINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 FOETAL EXPOSURE DURING PREGNANCY 2584
1 DRUG RESISTANCE 2014
2 DRUG EXPOSURE DURING PREGNANCY 1877
3 DRUG INTERACTION 1814
4 PYREXIA 1811
5 PAIN 1691
6 VIROLOGIC FAILURE 1579
7 NAUSEA 1561
8 ANAEMIA 1515
9 DEPRESSION 1468
See all common reactions for Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PINEALOBLASTOMA 76 0.8444
1 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 91 0.8273
2 GENOTYPE DRUG RESISTANCE TEST 39 0.7959
3 CSF HIV ESCAPE SYNDROME 80 0.6400
4 VIRAL MUTATION IDENTIFIED 1375 0.5603
5 IMMUNE RECONSTITUTION SYNDROME 685 0.5298
6 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 101 0.4856
7 VIROLOGIC FAILURE 1579 0.4502
8 AIDS ENCEPHALOPATHY 26 0.4483
9 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 35 0.4321
See all enriched reactions for Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]